Vir Biotechnology, Inc.
VIR
$5.09
-$0.325-6.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -73.79% | -13.90% | -33.82% | -83.93% | -82.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -73.79% | -13.90% | -33.82% | -83.93% | -82.16% |
| Cost of Revenue | -2.18% | -15.78% | -20.29% | -27.21% | -13.67% |
| Gross Profit | -10.82% | 16.11% | 17.16% | -179.70% | -185.01% |
| SG&A Expenses | -34.96% | -31.76% | -22.34% | -14.62% | -3.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.06% | -19.48% | -20.72% | -24.46% | -11.47% |
| Operating Income | 1.64% | 20.20% | 18.46% | -70.05% | -85.87% |
| Income Before Tax | -5.28% | 16.73% | 18.19% | -79.19% | -76.96% |
| Income Tax Expenses | 86.71% | 91.24% | 89.98% | 27.27% | 93.67% |
| Earnings from Continuing Operations | -7.08% | 15.14% | 11.22% | -84.35% | -275.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -100.00% | -100.00% | -100.00% |
| Net Income | -7.08% | 15.14% | 11.21% | -84.39% | -275.43% |
| EBIT | 1.64% | 20.20% | 18.46% | -70.05% | -85.87% |
| EBITDA | 0.76% | 20.05% | 18.81% | -72.09% | -86.47% |
| EPS Basic | -5.23% | 16.57% | 12.57% | -83.41% | -273.49% |
| Normalized Basic EPS | -1.11% | 22.76% | 26.11% | -73.74% | -76.88% |
| EPS Diluted | -5.12% | 16.65% | 12.47% | -81.70% | -265.97% |
| Normalized Diluted EPS | -1.11% | 22.76% | 26.11% | -71.12% | -74.56% |
| Average Basic Shares Outstanding | 1.66% | 1.58% | 1.44% | 1.30% | 1.19% |
| Average Diluted Shares Outstanding | 1.66% | 1.58% | 1.44% | 0.87% | 0.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |